Pharmaceutical News

RSS

PharmaVentures acts as advisor and broker to Dr Reddy's in distribution agreement with Vitabiotics

PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy's Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy's exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics' leading products - Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.

From Vitabiotics Ltd. 26 Oct 2010

PAREXEL's white paper provides data on biopharmaceutical, medical device product development

PAREXEL Consulting, a business unit of PAREXEL International and a leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released a new white paper entitled Drug Innovation, Approval, Market Access, and the New Normal Emerging FDA Review Outcome Trends for New Drugs.

From Parexel 26 Oct 2010

Independent drugstores expand and generate strong profits despite worst economy

Amidst the worst economy of the past seventy years, independent drugstores are expanding and generating strong profits, according to a new economic report by the National Community Pharmacists Association (NCPA). The report shows that there are almost 400 more independent drugstores than last year and that profits (3.2%) are three times greater than the rate of U.S. inflation (1.1%).

26 Oct 2010

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

26 Oct 2010

Admissions for medication, drug-related conditions increase by 117% among Americans aged 45 and older

The number of hospital admissions among Americans ages 45 and older for medication and drug-related conditions doubled between 1997 and 2008, according to a new report released today by HHS' Agency for Healthcare Research and Quality. Medication and drug-related conditions include effects of both prescription and over-the-counter medications as well as illicit drugs.

26 Oct 2010

Omeros to develop new drugs for major diseases

The Life Sciences Discovery Fund (LSDF) today announced a $5 million grant to Seattle-based Omeros Corporation (NASDAQ: OMER) to discover, develop, and commercialize new drugs to treat a variety of major diseases. With successful generation of proceeds through partnering and the sales of drugs in the marketplace, an additional outcome of the grant would be establishment of a new non-profit initiative to advance the life sciences sector and improve health and economic growth in Washington state.

26 Oct 2010

Pharmacopeias of US and Kazakhstan sign accord

With the mutual goal of improving the quality of pharmaceuticals worldwide, the United States Pharmacopeial Convention (USP) and the Republican State Enterprise (RSE) National Centre for Expertise of Drugs, Medical Products and Equipment ("the Centre") of the Ministry of Health of the Republic of Kazakhstan have entered into an agreement to share standards for the quality, purity, strength and identity of medicines.

26 Oct 2010

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of renal cell carcinoma (RCC), the majority of surveyed European oncologists who favor Pfizer's Sutent indicate that they would switch to an emerging therapy only if it extended progression-free survival (PFS) by at least an additional two to three months, assuming the agent's safety and tolerability profile was comparable to that of Sutent.

26 Oct 2010

IDC grants MedImmune global rights to GLA adjuvant

Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

26 Oct 2010

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Breast Cancer Awareness month spotlights the increasingly high incidence of breast cancer, and also brings attention to the question, "what is being done to speed and ease recovery?"

26 Oct 2010

Savient to evaluate strategic alternatives for KRYSTEXXA drug

Savient Pharmaceuticals, Inc. announced that its previously announced process to identify, following the approval of KRYSTEXXA by the U.S. Food and Drug Administration (FDA), a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value.

26 Oct 2010

AAHP highlights safety of homeopathic children's medicines

The American Association of Homeopathic Pharmacists (AAHP), representing the major manufacturers and distributors of homeopathic drugs, highlights the safety of homeopathic children's medicines in response to the recall of Hyland's Teething Tablets. The AAHP supports the efforts to protect the safety of children by both the Standard Homeopathic Company and the U.S. Food and Drug Administration (FDA).

26 Oct 2010

PhRMA representatives meet with officials in India to discuss compulsory licensing

During a visit with government officials, industry leaders and NGOs in India last week, representatives from Pharmaceutical Research and Manufacturers of America (PhRMA), a U.S. lobbying group that represents the country's pharmaceutical industry and biotechnology companies, addressed "the Indian government's proposal to allow local drugmakers to make low-cost version of patented drugs so that they can be made available to patients," the Economic Times reports.

26 Oct 2010

Aspirin reduces risk of death from prostate cancer

Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

26 Oct 2010

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.

26 Oct 2010

Baxter announces launch of GLASSIA in the U.S.

Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.

From Baxter International Inc. 26 Oct 2010

CBER's Laboratory Quality System program receives accreditation

The U.S. Food and Drug Administration today announced that the American Association for Laboratory Accreditation has accredited the Laboratory Quality System program in the Center for Biologics and Evaluation Research (CBER) under ISO/IEC 17025 in the fields of biological and chemical testing.

26 Oct 2010

S.A.N.E. Vax requests temporary suspension of Gardasil sales as cervical cancer preventive

In a letter addressed to Dr. Margaret Hamburg, the FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc. stated her research team has revealed the fact that in November 2001 the VRBPAC (Vaccines and Related Biological Products Advisory Committee) mistakenly allowed the vaccine manufacturer to use "CIN 2/3, AIS, or cervical cancer; i.e. CIN 2/3 or worse by histology- with virology to determine the associated HPV type- as the primary endpoint in the evaluation of a vaccine to prevent cervical cancer."

25 Oct 2010

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Immune Network Ltd. advises that a clinical trial of V5 Immunitor oral vaccine was published earlier this month demonstrating an unexpected powerful effect against tuberculosis, including multi-drug-resistant tuberculosis (MDR-TB) and tuberculosis that is complicated by co-infection with HIV and hepatitis C (HCV).

25 Oct 2010

Neptune launches Onemia medical food

Neptune Technologies & Bioressources Inc. enters the pharmaceutical market with the launch of Onemia™, the first medical food of Neptune's subsidiary Acasti Pharma Inc.. Only two years since its foundation, Acasti has completed the development and launch of "Onemia™" on October 21, 2010 at the Cardiometabolic Health Congress meeting in Boston.

25 Oct 2010

Pharmaceutical News

PharmaVentures acts as advisor and broker to Dr Reddy's in distribution agreement with Vitabiotics

PAREXEL's white paper provides data on biopharmaceutical, medical device product development

Independent drugstores expand and generate strong profits despite worst economy

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Admissions for medication, drug-related conditions increase by 117% among Americans aged 45 and older

Omeros to develop new drugs for major diseases

Pharmacopeias of US and Kazakhstan sign accord

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

IDC grants MedImmune global rights to GLA adjuvant

DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemotherapy

Savient to evaluate strategic alternatives for KRYSTEXXA drug

AAHP highlights safety of homeopathic children's medicines

PhRMA representatives meet with officials in India to discuss compulsory licensing

Aspirin reduces risk of death from prostate cancer

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Baxter announces launch of GLASSIA in the U.S.

CBER's Laboratory Quality System program receives accreditation

S.A.N.E. Vax requests temporary suspension of Gardasil sales as cervical cancer preventive

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Neptune launches Onemia medical food

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News